secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004080
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia restructures to focus on NTLA-2002 and nex-z, cuts 27% headcount, extends cash runway to H1 2027
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and investments of $862M as of Dec 31, 2024.
- Strategic restructuring: prioritize NTLA-2002 and nex-z; discontinue NTLA-3001 and select research programs.
- Net workforce reduction of approximately 27% in 2025; estimated $8M restructuring charges in Q1 2025.
- Cash runway extended to first half of 2027.
- CSO Laura Sepp-Lorenzino to retire Dec 31, 2025; Birgit Schultes promoted to EVP and CSO effective Jan 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/0001193125-25-004080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/d906527d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer